Trecento Santé ISR is an open-ended mutual fund (UCITS IV) that invests in shares of international companies from the healthcare sector (including pharmaceutical, biotechnology, diagnostics and medical technology companies, management of hospitals and health centers).

Its objective, for the recommended investment horizon of 5 years, is to achieve a net annualised return of more than 7% (share classes R EUR, R CHF and R USD) and more than 8% for the share class I EUR.

N.B: an institutional share class in euros (I EUR) has been launched on 12/31/2018.

Annual performance net of fees of the Trecento Santé ISR fund since its creation
2013 2014 2015 2016 2017 2018 2019 2020
16.06% 22.78% 12.86% -3.88% 1.93% 6.99% 14.80% 2.27%
R EUR Share – Performances at 03/02/2023
NAV YTD 1 month 1 year 3 years Creation
2 047,04€
-0,24%
-1,53%
-3,07%
+6,50%
+104,70%
NAV
2 047,04€
YTD
-0,24%
1 month
-1,53%
1 year
-3,07%
3 years
+6,50%
Creation
+104,70%
R USD Share – Performances at 03/02/2023
NAV YTD 1 month 1 year 3 years Inception (17/01/2017)
1 306,40 $
1,49%
+1,29%
--%
+3,57%
+30,64%
NAV
1 306,40 $
YTD 1,49%
1 month +1,29%
1 year --%
3 years +3,57%
Inception (17/01/2017)
+30,64%
R CHF Share – Performances at 03/02/2023
NAV YTD 1 month 1 year 3 years Inception (17/01/2017)
1 247,18 $
1,21%
-0,40%
--%
+0,67%
+24,72%
NAV
1 306,40 CHF
YTD 1,49%
1 month +1,29%
1 year --%
3 years +3,57%
Inception (17/01/2017)
+30,64%

ISIN code

R EUR Share – FR0011319664
I EUR Share – FR0013392461
R USD Share – FR0013224391
R CHF Share – FR0013224409

Legal form • Mutual Fund under the French law (FCP), UCITS IV compliant

Currency • Euro (€)

Launch date • 14/12/12

AMF Classification • International equities

Recommended investment horizon • 5 years

Valuation Period • Daily

Dividend Policy • Accumulation

Subscriptions/Redemptions• Cut-off: 16.30

Custodian • CACEIS Bank

Fund valuation • CACEIS Fund Administration

Auditors • Mazars

FATCA Status • Deemed-compliant FFI – Non reporting IGA FFI


Management fees
• 2% (incl. taxes) maximum for the R shares

• 1% (incl. taxes) maximum for the I EUR share

Entry fee • None

Exit fee • None

aliceAlice LHABOUZ

Founder & CEO

Alice LHABOUZ began her career at the Corporate Finance Division of Autorité des Marchés Financiers (AMF).

After working as a Buy-Side Financial Analyst at Richelieu Finance, Alice LHABOUZ joined La Financière Meeschaert in 2005 as a Private Portfolio Manager for French high-net-worth individuals and families.

In 2011, she founded Trecento Asset Management.

Alice LHABOUZ heads the company and, with Sothira NGAUV, manages the collective investment funds (mutual or dedicated) and is also the manager of discretionary investment mandates of private clients.

Sothira NGAUVSothira NGAUV

co Fund Manager

Sothira NGAUV holds a Master’s degree in Economics from Panthéon-Assas Paris II university, and a specialized Master’s degree in Finance from Audencia Business School. He started his career in the Asset Management Department of Autorité des Marchés Financiers (french financial markets regulator), then he had the opportunity to broaden his knowledges in financial analysis in the M&A Department of Crédit Agricole.

Sothira NGAUV joined Trecento AM in 2015 as a Financial analyst and currently serves as co-Manager of Trecento Santé ISR and Trecento Robotique ISR funds, and manages the SRI division. In 2014, he became interested in the topic of the socially responsible investment, by completing a professional thesis on the challenges and measurement of the financial performance of SRI UCITS, compared to traditional UCITS. In 2019, he led with success the SRI labeling project of the Trecento Santé and Trecento Robotique funds: they obtained the SRI label in the first quarter of 2020.

A leading healthcare expert committee, supporting the management team

This committee provides its experience and expertise to the management team to refine its product and sector market understanding.

Performance
R EUR Share – Performances at 03/02/2023
NAV YTD 1 month 1 year 3 years Creation
2 047,04€
-0,24%
-1,53%
-3,07%
+6,50%
+104,70%
NAV
2 047,04€
YTD
-0,24%
1 month
-1,53%
1 year
-3,07%
3 years
+6,50%
Creation
+104,70%
R USD Share – Performances at 03/02/2023
NAV YTD 1 month 1 year 3 years Inception (17/01/2017)
1 306,40 $
1,49%
+1,29%
--%
+3,57%
+30,64%
NAV
1 306,40 $
YTD 1,49%
1 month +1,29%
1 year --%
3 years +3,57%
Inception (17/01/2017)
+30,64%
R CHF Share – Performances at 03/02/2023
NAV YTD 1 month 1 year 3 years Inception (17/01/2017)
1 247,18 $
1,21%
-0,40%
--%
+0,67%
+24,72%
NAV
1 306,40 CHF
YTD 1,49%
1 month +1,29%
1 year --%
3 years +3,57%
Inception (17/01/2017)
+30,64%
Caracteristics

ISIN code

R EUR Share – FR0011319664
I EUR Share – FR0013392461
R USD Share – FR0013224391
R CHF Share – FR0013224409

Legal form • Mutual Fund under the French law (FCP), UCITS IV compliant

Currency • Euro (€)

Launch date • 14/12/12

AMF Classification • International equities

Recommended investment horizon • 5 years

Valuation Period • Daily

Dividend Policy • Accumulation

Subscriptions/Redemptions• Cut-off: 16.30

Custodian • CACEIS Bank

Fund valuation • CACEIS Fund Administration

Auditors • Mazars

FATCA Status • Deemed-compliant FFI – Non reporting IGA FFI


Management fees
• 2% (incl. taxes) maximum for the R shares

• 1% (incl. taxes) maximum for the I EUR share

Entry fee • None

Exit fee • None

Documents
The Fund Managers

aliceAlice LHABOUZ

Founder & CEO

Alice LHABOUZ began her career at the Corporate Finance Division of Autorité des Marchés Financiers (AMF).

After working as a Buy-Side Financial Analyst at Richelieu Finance, Alice LHABOUZ joined La Financière Meeschaert in 2005 as a Private Portfolio Manager for French high-net-worth individuals and families.

In 2011, she founded Trecento Asset Management.

Alice LHABOUZ heads the company and, with Sothira NGAUV, manages the collective investment funds (mutual or dedicated) and is also the manager of discretionary investment mandates of private clients.

Sothira NGAUVSothira NGAUV

co Fund Manager

Sothira NGAUV holds a Master’s degree in Economics from Panthéon-Assas Paris II university, and a specialized Master’s degree in Finance from Audencia Business School. He started his career in the Asset Management Department of Autorité des Marchés Financiers (french financial markets regulator), then he had the opportunity to broaden his knowledges in financial analysis in the M&A Department of Crédit Agricole.

Sothira NGAUV joined Trecento AM in 2015 as a Financial analyst and currently serves as co-Manager of Trecento Santé ISR and Trecento Robotique ISR funds, and manages the SRI division. In 2014, he became interested in the topic of the socially responsible investment, by completing a professional thesis on the challenges and measurement of the financial performance of SRI UCITS, compared to traditional UCITS. In 2019, he led with success the SRI labeling project of the Trecento Santé and Trecento Robotique funds: they obtained the SRI label in the first quarter of 2020.

The healthcare committee
A leading healthcare expert committee, supporting the management team

This committee provides its experience and expertise to the management team to refine its product and sector market understanding.

Past performance is not an indication of future results and may vary over time. Performances are calculated net of fees.
Data sources: Trecento AM

Trecento Santé ISR on video
The Healthcare Club

A healthcare club source of technology watch and skill sharing.. Each health professional subscriber is invited to join the Trecento healthcare club to share with us his “field” experience

Trecento Santé ISR on Twitter
@Durableo @AliceLHABOUZ @Poietis @marcfiorentino Bonjour, merci pour votre message. Oui nous connaissons, néanmoins… https://t.co/4DwvGvbylK
1
#Johnson&Johnson se renforce sur les maladies auto-immunes en rachetant #MomentaPharmaceuticals pour $6,5Mds (52,5$… https://t.co/xPiLRTwdAS
RT @sanofi: Sanofi CEO Paul Hudson: “This acquisition advances our ongoing R&D transformation to accelerate development of the most promisi…
31
RT @moderna_tx: We just announced interim results from the NIH-led Phase 1 Study of our #mRNA #vaccine against COVID-19 (mRNA-1273) in @NEJ…
RT @IpsenGroup: The @US_FDA grants Ipsen Fast Track designation for the development of 1st-line combination treatment for metastatic #pancr…
10
RT @FierceBiotech: The deal is the biggest one that Mads Krogsgaard Thomsen, in his 20 years as Novo Nordisk’s chief science officer, has e…
3
RT @illumina: COVIDSeq leverages the performance of NGS to help address the global need for diagnostic testing to fight the #COVID19 pandem…
72
Résultats d'étude de Ph III #ADAURA positifs impliquant #Tagrisso (osimertinib) en tant que traitement adjuvant dan… https://t.co/l9uILV4GHP
1
l'#Enhertu (trastuzumab deruxtecan) d'@AstraZeneca qualifié de "percée thérapeutique" par la #FDA aux US dans le c… https://t.co/3xVmRAAIGo
#Gilead rachète la biotech américaine Forty Seven pour $4,9Mds et renforce sa franchise oncologie en acquérant un a… https://t.co/3rxqZWNZpH
1 2
RT @FiercePharma: FDA reports first supply hit tied to COVID-19 https://t.co/j10eDEl04u
2
RT @FiercePharma: Bristol-Myers Squibb reaches tentative deal to end long-running Medicaid rebate lawsuit https://t.co/ktYvBrjfS8
1
RT @Trecento_Robot: #Medtronic renforce sa division #Robotique Chirurgicale et ses capacités d'#IA en rachetant Digital Surgery, société br…
4
Extension de collaboration entre #CELLINK3D et #AstraZeneca pour l'utilisation des bio-imprimantes 3D dans le cadre… https://t.co/7IwUPbDH82
2
RT @Roche: We are pleased to announce results from Part 2 of our FIREFISH study in infants aged between 1 and 7 months with type 1 #SMA. Th…
3
Approbation conditionnelle de la Commission Européenne pour le #Polivy en combinaison avec #bendamustine +… https://t.co/0Kpc2nvQ1M
1
#Imfinzi et #Tremelimumab obtiennent la désignation de médicaments orphelins de la part de la #FDA en tant que trai… https://t.co/sHeMh0Ey0e
1
@LillyPad va renforcer son pipeline en #immunologie et #dermatologie en rachetant #Dermira (US) pour $1,1Md (18,75$… https://t.co/8GCzh5loiO
Deux nouvelles acquisitions en #oncologie : #Sanofi acquiert la biotech américaine #Synthorx pour $2,5Mds, ou 68$/a… https://t.co/ZiOlIxKwGL
Le japonais #Astellas Pharma s'apprête à racheter la biotech américaine @AudentesTx spécialisée sur des traitements… https://t.co/UHPj9Aobpi